Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …

Abstract Gain of chromosome 1q (+ 1q) is one of the most common recurrent cytogenetic
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …

Purpose The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and
reliable tool is needed to stratify patients with MM. We combined the International Staging …

Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …

Virtually all patients with multiple myeloma become unresponsive to treatment over time.
Relapsed/refractory multiple myeloma (RRMM) is accompanied by the clonal evolution of …

Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which
translates to variable response to treatment and outcome. With the recent increase in …

Purpose We investigated whether bortezomib during induction and maintenance improves
survival in newly diagnosed multiple myeloma (MM). Patients and Methods In all, 827 …

To date, the choice of therapy for an individual multiple myeloma patient has been based on
clinical factors such as age and comorbidities. The widespread evolution, validation, and …

The interpretation of cytogenetic abnormalities in multiple myeloma (MM) is often a
challenging task. MM is characterized by several cytogenetic abnormalities that occur at …

The association of genetic lesions detected by fluorescence in situ hybridization (FISH) with
survival was analyzed in 1069 patients with newly presenting myeloma treated in the …